CVS financials
CVS Health Corp. · end-of-day data as of Oct 16, 2026
CVS Health Corp.
$92.36-14.3%
Buy · 27 analystsPT $111.66 +20.9%
CVS reported revenue of $106B for the quarter ended Jun 30, 2026 (Q2 FY2026), up 7.3% from a year earlier. It posted diluted EPS of $2.31, free cash flow of $5.65B and a net margin of 2.8%.
Valuation
- P/E24.4x
- P/E vs own-69.0%
- P/E vs sector-13.2%
- FCF yield+10.0%
- Market cap$118B
Quarterly results
Q2 FY2026: Revenue +7.3% year over year, free cash flow 5.3% of revenue, operating margin 4.4%.
RevenueFree cash flow
| Q2 FY2026 | Jun 30, 2026 | $106B | 2.31 | $5.65B | 14.8% | 4.4% | 2.8% |
| Q1 FY2026 | Mar 31, 2026 | $100B | 2.30 | $3.4B | 15.6% | 4.7% | 2.9% |
| Q4 FY2025 | Dec 31, 2025 | $106B | 2.30 | $2.61B | 12.8% | 2.0% | 2.8% |
| Q3 FY2025 | Sep 30, 2025 | $103B | -3.13 | $98M | 13.4% | -3.1% | -3.9% |
| Q2 FY2025 | Jun 30, 2025 | $98.92B | 0.80 | $1.29B | 13.7% | 2.4% | 1.0% |
| Q1 FY2025 | Mar 31, 2025 | $94.59B | 1.41 | $3.81B | 15.2% | 3.6% | 1.9% |
| Q4 FY2024 | Dec 31, 2024 | $97.71B | 1.30 | $1.09B | 13.2% | 2.4% | 1.7% |
| Q3 FY2024 | Sep 30, 2024 | $95.43B | 0.07 | -$1.42B | 13.2% | 0.9% | 0.1% |
| Q2 FY2024 | Jun 30, 2024 | $91.23B | 1.41 | $2.45B | 14.7% | 3.3% | 1.9% |
| Q1 FY2024 | Mar 31, 2024 | $88.44B | 0.88 | $4.2B | 14.2% | 2.6% | 1.3% |
| Q4 FY2023 | Dec 31, 2023 | $93.81B | 1.59 | -$3.55B | 14.8% | 3.6% | 2.2% |
| Q3 FY2023 | Sep 30, 2023 | $89.76B | 1.75 | $2.17B | 15.1% | 4.1% | 2.5% |